 Sheryl Vondracek
Concepts (122)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Osteoporosis | 5 | 2009 | 224 | 1.210 |
Why?
| | Antihypertensive Agents | 2 | 2018 | 428 | 0.880 |
Why?
| | Vitamin D | 6 | 2012 | 340 | 0.850 |
Why?
| | Nephrologists | 1 | 2021 | 12 | 0.750 |
Why?
| | Bone Density Conservation Agents | 3 | 2010 | 62 | 0.670 |
Why?
| | Hypertension | 2 | 2018 | 1052 | 0.650 |
Why?
| | Vitamin D Deficiency | 5 | 2012 | 158 | 0.600 |
Why?
| | Glomerular Filtration Rate | 1 | 2021 | 605 | 0.600 |
Why?
| | Labetalol | 1 | 2018 | 5 | 0.600 |
Why?
| | Adrenergic Antagonists | 1 | 2018 | 8 | 0.590 |
Why?
| | Hydralazine | 1 | 2018 | 5 | 0.590 |
Why?
| | Kidney Diseases | 1 | 2021 | 349 | 0.580 |
Why?
| | Asymptomatic Diseases | 1 | 2016 | 75 | 0.520 |
Why?
| | Vasodilator Agents | 1 | 2018 | 302 | 0.510 |
Why?
| | Pulmonary Disease, Chronic Obstructive | 3 | 2009 | 907 | 0.500 |
Why?
| | Curriculum | 1 | 2021 | 813 | 0.490 |
Why?
| | Ergocalciferols | 2 | 2012 | 11 | 0.490 |
Why?
| | Kidney | 1 | 2021 | 1182 | 0.470 |
Why?
| | Bone Density | 4 | 2015 | 432 | 0.470 |
Why?
| | Hospitalization | 2 | 2018 | 1762 | 0.390 |
Why?
| | Glucocorticoids | 2 | 2006 | 526 | 0.380 |
Why?
| | Blood Pressure | 1 | 2018 | 1531 | 0.380 |
Why?
| | Receptors, Calcitriol | 1 | 2011 | 53 | 0.370 |
Why?
| | Body Composition | 2 | 2015 | 590 | 0.350 |
Why?
| | Prescription Drugs | 1 | 2012 | 116 | 0.340 |
Why?
| | Osteoporosis, Postmenopausal | 1 | 2010 | 36 | 0.340 |
Why?
| | Adipokines | 1 | 2009 | 42 | 0.320 |
Why?
| | Geriatric Nursing | 1 | 2009 | 15 | 0.320 |
Why?
| | Premenopause | 1 | 2009 | 105 | 0.310 |
Why?
| | Risk Reduction Behavior | 1 | 2010 | 200 | 0.300 |
Why?
| | Administration, Intravenous | 2 | 2018 | 122 | 0.270 |
Why?
| | Kidney Failure, Chronic | 1 | 2011 | 489 | 0.260 |
Why?
| | Prednisone | 1 | 2006 | 229 | 0.240 |
Why?
| | Acute Disease | 3 | 2018 | 908 | 0.230 |
Why?
| | Hospitals, University | 2 | 2018 | 169 | 0.200 |
Why?
| | Severity of Illness Index | 3 | 2018 | 2537 | 0.190 |
Why?
| | Aged | 8 | 2018 | 18971 | 0.170 |
Why?
| | Drug Therapy, Combination | 3 | 2015 | 949 | 0.160 |
Why?
| | Electronic Health Records | 2 | 2018 | 799 | 0.150 |
Why?
| | Absorptiometry, Photon | 2 | 2009 | 224 | 0.150 |
Why?
| | Humans | 18 | 2021 | 114050 | 0.150 |
Why?
| | Drug Utilization Review | 1 | 2018 | 56 | 0.140 |
Why?
| | Time Factors | 2 | 2018 | 6077 | 0.140 |
Why?
| | Pharmacists | 2 | 2010 | 231 | 0.140 |
Why?
| | Aged, 80 and over | 5 | 2012 | 6307 | 0.130 |
Why?
| | Vitamins | 2 | 2008 | 150 | 0.130 |
Why?
| | Blood Pressure Determination | 1 | 2016 | 122 | 0.130 |
Why?
| | Administration, Oral | 1 | 2018 | 725 | 0.120 |
Why?
| | Estrogens, Conjugated (USP) | 1 | 2015 | 34 | 0.120 |
Why?
| | Female | 10 | 2018 | 59328 | 0.110 |
Why?
| | Gonadotropin-Releasing Hormone | 1 | 2015 | 189 | 0.110 |
Why?
| | Drug Administration Schedule | 2 | 2006 | 714 | 0.110 |
Why?
| | Fractures, Bone | 2 | 2009 | 367 | 0.110 |
Why?
| | Colorado | 4 | 2018 | 4090 | 0.100 |
Why?
| | Exercise | 2 | 2015 | 1642 | 0.100 |
Why?
| | Prevalence | 2 | 2016 | 2247 | 0.100 |
Why?
| | Retrospective Studies | 3 | 2018 | 12521 | 0.100 |
Why?
| | Drug Evaluation | 1 | 2012 | 77 | 0.100 |
Why?
| | Male | 8 | 2018 | 55400 | 0.100 |
Why?
| | Dose-Response Relationship, Drug | 2 | 2015 | 1837 | 0.100 |
Why?
| | Professional Role | 2 | 2010 | 148 | 0.090 |
Why?
| | Cholecalciferol | 1 | 2011 | 47 | 0.090 |
Why?
| | Bone Resorption | 1 | 2011 | 73 | 0.090 |
Why?
| | Contraindications | 1 | 2010 | 84 | 0.090 |
Why?
| | Adult | 4 | 2018 | 30377 | 0.080 |
Why?
| | Resistin | 1 | 2009 | 12 | 0.080 |
Why?
| | Bone Remodeling | 1 | 2010 | 65 | 0.080 |
Why?
| | Practice Patterns, Physicians' | 1 | 2018 | 1175 | 0.080 |
Why?
| | Middle Aged | 3 | 2018 | 26607 | 0.080 |
Why?
| | Biological Factors | 1 | 2009 | 35 | 0.080 |
Why?
| | Practice Guidelines as Topic | 1 | 2016 | 1381 | 0.080 |
Why?
| | Hip Joint | 1 | 2009 | 124 | 0.080 |
Why?
| | Raloxifene Hydrochloride | 1 | 2008 | 13 | 0.070 |
Why?
| | Leptin | 1 | 2009 | 210 | 0.070 |
Why?
| | Adiponectin | 1 | 2009 | 213 | 0.070 |
Why?
| | Risk Assessment | 1 | 2016 | 2958 | 0.070 |
Why?
| | Diphosphonates | 1 | 2008 | 51 | 0.070 |
Why?
| | Lumbar Vertebrae | 1 | 2009 | 207 | 0.070 |
Why?
| | Accreditation | 1 | 2007 | 76 | 0.070 |
Why?
| | Treatment Outcome | 2 | 2018 | 9049 | 0.070 |
Why?
| | Community Pharmacy Services | 1 | 2007 | 42 | 0.070 |
Why?
| | Calcium | 2 | 2010 | 1089 | 0.070 |
Why?
| | Women's Health | 1 | 2009 | 270 | 0.070 |
Why?
| | Life Style | 1 | 2009 | 428 | 0.070 |
Why?
| | Pharmacy Service, Hospital | 1 | 2007 | 83 | 0.070 |
Why?
| | Hospital Bed Capacity, 300 to 499 | 1 | 2006 | 4 | 0.070 |
Why?
| | Drug Administration Routes | 1 | 2006 | 38 | 0.070 |
Why?
| | Preceptorship | 1 | 2006 | 62 | 0.060 |
Why?
| | Education, Pharmacy | 1 | 2007 | 121 | 0.060 |
Why?
| | Risk Factors | 3 | 2009 | 8614 | 0.060 |
Why?
| | Students, Pharmacy | 1 | 2006 | 97 | 0.060 |
Why?
| | Drug Utilization | 1 | 2006 | 164 | 0.060 |
Why?
| | Pilot Projects | 1 | 2009 | 1360 | 0.060 |
Why?
| | Educational Measurement | 1 | 2006 | 235 | 0.060 |
Why?
| | Tumor Necrosis Factor-alpha | 1 | 2009 | 1128 | 0.060 |
Why?
| | Patient Education as Topic | 1 | 2008 | 666 | 0.060 |
Why?
| | Recurrence | 1 | 2006 | 925 | 0.050 |
Why?
| | Mass Screening | 1 | 2009 | 979 | 0.050 |
Why?
| | Cross-Sectional Studies | 2 | 2009 | 4402 | 0.050 |
Why?
| | Clinical Trials as Topic | 1 | 2006 | 926 | 0.050 |
Why?
| | Clinical Competence | 1 | 2007 | 882 | 0.040 |
Why?
| | Diet | 1 | 2007 | 1080 | 0.040 |
Why?
| | Parathyroid Hormone | 2 | 2008 | 96 | 0.030 |
Why?
| | Lung | 1 | 2009 | 3521 | 0.030 |
Why?
| | Young Adult | 1 | 2012 | 10446 | 0.030 |
Why?
| | Prognosis | 1 | 2004 | 3315 | 0.030 |
Why?
| | Ovary | 1 | 2015 | 190 | 0.030 |
Why?
| | Ambulatory Care | 2 | 2008 | 479 | 0.030 |
Why?
| | Adolescent | 1 | 2012 | 17802 | 0.030 |
Why?
| | Self Administration | 1 | 2008 | 122 | 0.020 |
Why?
| | Pharmaceutical Services | 1 | 2008 | 76 | 0.020 |
Why?
| | Nutrition Policy | 1 | 2007 | 54 | 0.020 |
Why?
| | Phosphorus | 1 | 2007 | 81 | 0.020 |
Why?
| | Nonprescription Drugs | 1 | 2007 | 68 | 0.020 |
Why?
| | Serum Albumin | 1 | 2007 | 137 | 0.020 |
Why?
| | Schools, Pharmacy | 1 | 2006 | 48 | 0.020 |
Why?
| | Creatinine | 1 | 2007 | 424 | 0.020 |
Why?
| | Outpatients | 1 | 2007 | 325 | 0.010 |
Why?
| | Age Factors | 1 | 2007 | 2886 | 0.010 |
Why?
| | Follow-Up Studies | 1 | 2008 | 4392 | 0.010 |
Why?
| | Prospective Studies | 1 | 2007 | 6195 | 0.010 |
Why?
| | Obesity | 1 | 2007 | 2505 | 0.010 |
Why?
|
|
Vondracek's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|